Seres Therapeutics (MCRB) to Release Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is set to announce its earnings results before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. During the same quarter last year, the firm posted $0.36 EPS. On average, analysts expect Seres Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Seres Therapeutics Price Performance

Shares of NASDAQ MCRB opened at $0.74 on Thursday. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $2.05. The firm has a market capitalization of $125.95 million, a P/E ratio of -0.64 and a beta of 2.06. The company’s 50 day simple moving average is $0.88 and its 200 day simple moving average is $0.92.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. StockNews.com lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. Chardan Capital restated a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday, August 14th. Canaccord Genuity Group restated a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Friday, September 13th. Finally, JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.